94
Fig. 6.4 MRI visualizing tumor growth and effect of Exp-NK cells in myelomatous mouse. NOD/
SCID/IL2Rγnull-hu mice were engrafted with OPM2 myeloma cells and treated with 160 M
Exp-NK cells. The mice were imaged to determine the baseline, after 2–4 weeks for myeloma
growth (Control, upper panel) and evaluated for Exp-NK cell therapy-mediated changes (bottom
panel). In control, an enlarged extramedullary tumor is observed with good soft tissue contrast
compare to Exp-NK treated group where the bone integrity is well protected with a significantly
reduced tumor
Fig. 6.5 Inhibition of primary myeloma growth visualized by MRI and FDG-PET scan. NOD/
SCID/IL2Rγnull-hu mice were engrafted with primary myeloma cells. The mice were scanned for
the tumor load by MRI and metabolic activity by FDG-PET imaging. (a) MRI revealed macro-
scopic morphology, gross loss of bone and enlarged tumor mass in the control mouse. (b) Mouse
received 160 M expanded NK cells maintained the bone structure with no visible tumor mass
compare to the control mouse. (c) High^18 F–FDG uptake in control mouse confirmed higher tumor
load by FDG-PET imaging. (d) No active tumor was detected in Exp-NK cell treated mouse
T.K. Garg and T. Pandey